Heartflow to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference
Heartflow (Nasdaq: HTFL), a leader in AI-powered coronary artery disease technology, has announced its participation in the Morgan Stanley 23rd Annual Global Healthcare Conference.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Heartflow (Nasdaq: HTFL), a leader in AI-powered coronary artery disease technology, has announced its participation in the Morgan Stanley 23rd Annual Global Healthcare Conference. The company's management will engage in a fireside chat scheduled for September 10, 2025, at 6:15 a.m. PT / 9:15 a.m. ET.
Investors can access both live and archived versions of the presentation through Heartflow's Investor Relations website at ir.heartflow.com.
Details
News Market Reaction – HTFL
On Aug 28, the first trading day after this news, HTFL closed 7.54% below the previous close.
Data tracked by StockTitan Argus for the Aug 28 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
MOUNTAIN VIEW, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Heartflow, Inc. (Heartflow) (Nasdaq: HTFL), the leader in AI technology for coronary artery disease (CAD), today announced that members of management will participate in a fireside chat at the upcoming Morgan Stanley 23rd Annual Global Healthcare Conference. The fireside chat will take place on Wednesday, September 10, 2025, at 6:15 a.m. PT / 9:15 a.m. ET.
A live and archived version of the fireside chat will be available on the Investor Relations section of the Heartflow website at https://ir.heartflow.com.
About Heartflow, Inc.
Heartflow is advancing coronary care by transforming coronary artery disease into a screenable, diagnosable, and manageable condition. Heartflow One is the only complete, non-invasive, precision coronary care platform providing patient insights throughout the guideline-directed CCTA pathway. The AI-driven platform — including Roadmap™ Analysis, FFRCT Analysis and Plaque Analysis — is supported by the ACC/AHA Chest Pain Guideline and backed by more than 600 peer-reviewed publications. Heartflow has helped clinicians manage over 400,000 patients worldwide. Discover how we’re shaping the future of cardiovascular care at www.heartflow.com.
Investor Contact
Nick Laudico
nlaudico@heartflow.com
Media Contact
Elliot Levy
elevy@heartflow.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.